Wednesday, July 8, 2026

pharma · Obesity · Obesity With Diabetes · KLRA

Kailera Therapeutics

Kailera Therapeutics clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Waltham, USA HQ
2024 Founded
153 Employees
Public company Type
KLRA · NYSE Ticker
Company details
Intelligence · Clinical Programs

Kailera Therapeutics projects

5 ClinicalTrials.gov programs sponsored by Kailera Therapeutics.

Kailera Therapeutics has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. K9531-3103

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial
  2. K9531-3104

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial
  3. K9531-3107

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial
  4. KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    3 trials
  5. KAI-9531

    Kailera Therapeutics

    Obesity With Diabetes

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Kailera Therapeutics have?

5 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.